- Home
- TBBK vs RCKT Comparison
TBBK vs RCKT Comparison
Compare TBBK & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TBBK | RCKT |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 394.2M |
| IPO Year | 2005 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TBBK | RCKT |
|---|---|---|
| Price | $50.20 | $3.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $69.00 | $29.73 |
| AVG Volume (30 Days) | 490.4K | ★ 1.4M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.69 | ★ 26.37 |
| EPS | ★ 2.86 | 0.66 |
| Revenue | ★ $141,147,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.16 | $64.28 |
| P/E Ratio | $17.71 | ★ $5.30 |
| Revenue Growth | ★ 20.85 | N/A |
| 52 Week Low | $48.41 | $2.53 |
| 52 Week High | $81.65 | $5.45 |
Technical Indicators
Market Signals| Indicator | TBBK | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 22.33 | 46.13 |
| Support Level | N/A | $3.36 |
| Resistance Level | $56.38 | $3.65 |
| Average True Range (ATR) | 1.88 | 0.20 |
| MACD | -1.22 | -0.03 |
| Stochastic Oscillator | 8.68 | 31.54 |
Price Performance
Historical ComparisonAbout TBBK The Bancorp Inc
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, Credit Solutions (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Credit Solutions includes REBL (real estate bridge lending), comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.